HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support.

AbstractBACKGROUND:
Radiolabeled monoclonal antibodies recognizing B-lymphocyte surface antigens represent a potentially effective new therapy for lymphomas. We assessed the biodistribution, toxicity, and efficacy of anti-CD20 (B1 and 1F5) and anti-CD37 (MB-1) antibodies labeled with iodine-131 in 43 patients with B-cell lymphoma in relapse.
METHODS:
Sequential biodistribution studies were performed with escalating doses of antibody (0.5, 2.5, and 10 mg per kilogram of body weight) trace-labeled with 5 to 10 mCi of 131I. The doses of radiation absorbed by tumors and normal organs were estimated by serial gamma-camera imaging and tumor biopsies. Patients whose tumors were estimated to receive greater doses of radiation than the liver, lungs, or kidneys (i.e., patients with a favorable biodistribution) were eligible for therapeutic infusion of 131I-labeled antibodies according to a phase 1 dose-escalation protocol.
RESULTS:
Twenty-four patients had a favorable biodistribution, and 19 received therapeutic infusions of 234 to 777 mCi of 131I-labeled antibodies (58 to 1168 mg) followed by autologous marrow reinfusion, resulting in complete remission in 16, a partial response in 2, and a minor response (25 to 50 percent regression of tumor) in 1. Nine patients have remained in continuous complete remission for 3 to 53 months. Toxic effects included myelosuppression, nausea, infections, and two episodes of cardiopulmonary toxicity, and were moderate in patients treated with doses of 131I-labeled antibodies that delivered less than 27.25 Gy to normal organs.
CONCLUSIONS:
High-dose radioimmunotherapy with 131I-labeled antibodies is associated with a high response rate in patients with B-cell lymphoma in whom antibody biodistribution is favorable.
AuthorsO W Press, J F Eary, F R Appelbaum, P J Martin, C C Badger, W B Nelp, S Glenn, G Butchko, D Fisher, B Porter
JournalThe New England journal of medicine (N Engl J Med) Vol. 329 Issue 17 Pg. 1219-24 (Oct 21 1993) ISSN: 0028-4793 [Print] UNITED STATES
PMID7692295 (Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antibodies, Monoclonal
  • Antigens, CD
  • Antigens, CD20
  • Antigens, Differentiation, B-Lymphocyte
  • Antigens, Neoplasm
  • CD37 protein, human
  • Glycoproteins
  • Iodine Radioisotopes
  • Tetraspanins
Topics
  • Antibodies, Monoclonal
  • Antigens, CD (immunology)
  • Antigens, CD20
  • Antigens, Differentiation, B-Lymphocyte (immunology)
  • Antigens, Neoplasm
  • Bone Marrow Transplantation
  • Combined Modality Therapy
  • Glycoproteins (immunology)
  • Humans
  • Iodine Radioisotopes (administration & dosage, adverse effects, pharmacokinetics)
  • Lymphoma, B-Cell (metabolism, physiopathology, radiotherapy, therapy)
  • Middle Aged
  • Radioimmunotherapy
  • Remission Induction
  • Spleen (physiopathology)
  • Tetraspanins
  • Transplantation, Autologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: